Federal Register of Legislation - Australian Government

Primary content

PB 42 of 2021 Arrangements as made
This instrument amends the National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021) to add, delete and make changes to drugs, forms, manners of administration, brands, authorised prescribers, maximum quantities and repeats and the circumstances for prescribing various pharmaceutical benefits (including authority requirements).
Administered by: Health
Registered 30 Apr 2021
Tabling HistoryDate
Tabled HR11-May-2021
Tabled Senate11-May-2021
To be repealed 12 Aug 2021
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 42 of 2021

 

National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (May Update) Instrument 2021

 

National Health Act 1953

___________________________________________________________________________

 

I, BEN SLADIC, Assistant Secretary, Pharmacy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Amendment Instrument under subsection 100(2) of the National Health Act 1953.

 

Dated          28 April              2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BEN SLADIC

Assistant Secretary

Pharmacy Branch

Technology Assessment and Access Division

Department of Health


 

 

___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (May Update) Instrument 2021.

(2)          This Instrument may also be cited as PB 42 of 2021.

2          Commencement

This Instrument commences on 1 May 2021.

3          Amendment of National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)

Schedule 1 amends the National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021).

 

 


Schedule 1     Amendments

[1]        Schedule 1, entry for Tenofovir with emtricitabine in the form Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

CIPLA TENOFOVIR + EMTRICITABINE 300/200

C6985 C6986

 

60

5